The 12-month trial is on target to hit its target of delivering the smart phone pain assessment and monitoring device to 100,000 Australians living with dementia.
Contracted RACs increased from 160 to 380 (or 238%) across Australia, NZ, Singapore and the UK during the quarter to 31 December 2019.
31,564 beds (98.6%) of these contracted beds are in Australia, representing a 15% penetration level into the market here.
PainChek – which automatically detects pain via artificial intelligence and facial recognition technology in people who are unable to communicate – also added another nine clients in January, bringing its total RACs to 411 and total contracted beds to 34,402.
As we covered here, the Government is funding the trial to the tune of $5 million in 2020.
You can fill in an expression of interest HERE.
